China creates effective biotech standards independent of US leadership– They’re creating ethical international norms now
Terry 22 (Mark Terry, “China Introduces Strict New Bioethics for Genetics Materials”, BioSpace, April 29th 2022, https://www.biospace.com/article/china-introduces-new-bioethics-guidelines-for-genetics-materials/, WC-NAS)
China recently new for bioethics related to human genetic resources. Reportedly, these will “clarify jurisdictions of regulatory bodies and enhance supervision related to biopharmaceutical research.”
The country’s new proposed rules define human genetic resources, according to the Genetic Literacy Project, “as genetic materials, including organs, tissues and cells, as well as genetic information, such as the human genome and genes.”
The proposed guidelines also state that organizations and individuals outside of China, as well as groups formed or controlled by foreign stakeholders, cannot collect and preserve Chinese human genetic resources inside China or take them outside of the country. “The collection, storage and supply of Chinese human genetic resources must be carried out by Chinese scientific research institutions, universities, medical institutions and enterprises, it added.”
The proposal was presented by the Chinese Ministry of Science and Technology. It is currently in a public consultation phase. Last year, the country’s Biosecurity Law and Data Security Law both took effect.
For several decades, the U.S., Brazil, Japan and much of Europe have bolstered their management of human genetic resources. Chu Jiayou, former director of the Institute of Medical Biology of the , said, “This subject has gradually become a field with global strategic importance.”
The new rules could potentially affect a broad range of scientific studies ranging from archaeology to agriculture to medicine. British law firm Simmons & Simmons suggests it could hamper international cooperation in biomedical research. The rules also define a foreign-controlled entity as any organization in which foreigners (outside China) hold more than 50% of equity or wield significant influence over decision-making, internal management and contracts or arrangements.
The draft emphasizes data security associated with human genetic resources. It appears to build on a regulatory framework on human genetic resources China issued in 2019 by the State Council, China’s Cabinet.
The chief scientist of a Tianjin-based biotech company who requested anonymity was quoted by China Daily, saying, “It is a very instructive and meticulous piece of regulation that will have a lasting impact on how bio-research will be conducted in China and with global partners. Bioethics regarding human genetic research has always been a pressing issue for the global biotechnology sector. I believe China’s latest effort to optimize its management of human genetic resources will ensure the positive growth of its bio-industry.”